179 related articles for article (PubMed ID: 22351250)
1. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
[TBL] [Abstract][Full Text] [Related]
2. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
3. Intradural chordoma presenting with intratumoral bleeding.
Vellutini Ede A; de Oliveira MF
J Clin Neurosci; 2016 Mar; 25():139-42. PubMed ID: 26563604
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas.
Lin E; Scognamiglio T; Zhao Y; Schwartz TH; Phillips CD
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1509-1514. PubMed ID: 29903925
[TBL] [Abstract][Full Text] [Related]
6. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
7. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
8. Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas.
Pamir MN; Ozduman K
Eur J Radiol; 2006 Jun; 58(3):461-70. PubMed ID: 16631334
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
10. Expression of Cathepsin K in Skull Base Chordoma.
Tian K; Ma J; Wang L; Wang K; Li D; Hao S; Yang Y; Du J; Jia G; Zhang L; Wu Z; Zhang J
World Neurosurg; 2017 May; 101():396-404. PubMed ID: 28216213
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
13. Natural Growth Dynamics of Untreated Skull Base Chordomas In Vivo.
Wang K; Xie SN; Wang L; Du J; Ma JP; Huo XL; Tian KB; Zhang LW; Zhang JT; Wu Z
World Neurosurg; 2020 Apr; 136():e310-e321. PubMed ID: 31926359
[TBL] [Abstract][Full Text] [Related]
14. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.
Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE
Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322
[TBL] [Abstract][Full Text] [Related]
15. [Dedifferentiated chordoma of the skull base. A case report].
Sefiani S; Amarti A; Maher M; Benkiran L; Saidi A
Neurochirurgie; 2002 Nov; 48(5):436-9. PubMed ID: 12483123
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the "Sekhar grading system for cranial Chordomas" in patients treated with pencil beam scanning proton therapy: an institutional analysis.
Hottinger AL; Bojaxhiu B; Ahlhelm F; Walser M; Bachtiary B; Zepter S; Lomax T; Pica A; Weber DC
Radiat Oncol; 2020 May; 15(1):96. PubMed ID: 32375820
[TBL] [Abstract][Full Text] [Related]
18. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
19. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
20. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]